Oncomine Myeloid Assay (OMA)
R21 750
A targeted NGS panel for haematological malignancies. Identifies somatic variants relevant to myeloid cancers including AML, MDS, and MPN to guide diagnosis and treatment decisions.
Oncomine Myeloid Assay (Myeloid OMA)
An NGS assay for myeloid tumour profiling from a diagnostic tissue sample. The Oncomine Myeloid Assay analyses 17 full genes, 28 hot-spot genes, and 34 fusion variants, identifying specific disease sub-classes and clinically actionable mutations. This genomic profile helps select the most targeted and effective treatment options for the patient’s specific cancer type, supporting improved patient outcomes.
- Sample types: whole blood, peripheral blood leukocytes (PBLs), or bone marrow
- Analyses 17 full genes, 28 hot-spot genes, and 34 fusion variants
- Identifies specific disease sub-classes
- Detects clinically actionable mutations across multiple genes
- Supports targeted treatment selection for myeloid cancers
Be the first to review “Oncomine Myeloid Assay (OMA)”
Related products
Whole genome sequencing
R15 500
Nutrigenomics Premier
R6 850
PGx Static
R5 900
PGx Live
R7 500
Nutrigenomics Standard
R3 900
Familial mutation
R1 400
DPYD Test
R4 650
Reviews
There are no reviews yet.